Oncology Central

Future prospects of therapeutic clinical trials in acute myeloid leukemia

0

Acute myeloid leukemia (AML) is a markedly heterogeneous hematological malignancy that is most commonly seen in elderly adults. The response to current therapies to AML is quite variable, and very few new drugs have been recently approved for use in AML. This review aims to discuss the issues with current trial design for AML therapies, including trial end points, patient enrollment, cost of drug discovery and patient heterogeneity.  We also discuss

To view restricted content, please:
Share:

Leave A Comment